ES2112921T3 - Peptidos y anticuerpos para el tratamiento de la artritis reumatoide. - Google Patents

Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.

Info

Publication number
ES2112921T3
ES2112921T3 ES92923909T ES92923909T ES2112921T3 ES 2112921 T3 ES2112921 T3 ES 2112921T3 ES 92923909 T ES92923909 T ES 92923909T ES 92923909 T ES92923909 T ES 92923909T ES 2112921 T3 ES2112921 T3 ES 2112921T3
Authority
ES
Spain
Prior art keywords
peptides
antibodies
treatment
rheumatoid arthritis
necessarily adjacent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92923909T
Other languages
English (en)
Inventor
Julian Kirby
Ian Victor Lewin
Sarita Maman
Denis Raymond Stanworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Application granted granted Critical
Publication of ES2112921T3 publication Critical patent/ES2112921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN PEPTIDO SINTETICO DE NO MAS DE 20 RESIDUOS DE AMINOACIDOS O ANALOGOS DE ELLOS, COMPRENDE UN RESIDUO DE CISTEINA TIOL-ACTIVA Y AL MENOS DOS RESIDUOS DE AMINOACIDOS CARGADOS POSITIVAMENTE SITUADOS SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) EL LATERAL TERMINAL-N, SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) EL LATERAL TERMINAL-C O SOBRE (PERO NO NECESARIAMENTE ADYACENTES A ) AMBOS TERMINALES-C,-N DE LA CISTEINA TIOL-ACTIVA DE USO TERAPEUTICO.
ES92923909T 1991-11-25 1992-11-25 Peptidos y anticuerpos para el tratamiento de la artritis reumatoide. Expired - Lifetime ES2112921T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919125024A GB9125024D0 (en) 1991-11-25 1991-11-25 Rheumatoid arthritus treatment

Publications (1)

Publication Number Publication Date
ES2112921T3 true ES2112921T3 (es) 1998-04-16

Family

ID=10705197

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92923909T Expired - Lifetime ES2112921T3 (es) 1991-11-25 1992-11-25 Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.

Country Status (10)

Country Link
EP (1) EP0614464B1 (es)
JP (1) JPH07507045A (es)
AT (1) ATE163939T1 (es)
AU (2) AU2951392A (es)
CA (1) CA2123694A1 (es)
DE (1) DE69224750D1 (es)
ES (1) ES2112921T3 (es)
FI (1) FI942392A0 (es)
GB (2) GB9125024D0 (es)
WO (1) WO1993011153A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416865D0 (en) * 1994-08-19 1994-10-12 Peptide Therapeutrics Limited Treatment of inflammatory diseases of the gastro-intestinal tract
GB9416864D0 (en) * 1994-08-19 1994-10-12 Peptide Therapeutrics Limited Treatment of IgA nephropathy
IL115744A (en) * 1994-10-27 2000-07-16 Akzo Nobel Nv Peptides comprising a subsequence of human cartilage glycoprotein - 39
KR100584051B1 (ko) 1996-03-01 2006-05-30 노파르티스 아게 알레르기에 대한 백신 접종 및 치료를 위한 펩티드임뮤노겐
AU2001270098A1 (en) * 2000-06-22 2002-01-02 San Diego State University Foundation Recombination modulators and methods for their production and use
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US11918624B2 (en) 2020-06-10 2024-03-05 Kelsius Laboratories LLC Therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2938420A1 (de) * 1979-09-22 1981-04-09 Hoechst Ag, 6000 Frankfurt Neue peptide und verfahren zu ihrer herstellung
AU572173B2 (en) * 1983-08-29 1988-05-05 Institut De Recherches Cliniques De Montreal Natriuretic factors
US4701416A (en) * 1983-12-09 1987-10-20 Cetus Corporation Feline leukemia virus vaccine plasmids for fusion protein of the gp70 envelope protein of FELV
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
CA1327096C (en) * 1985-12-26 1994-02-15 Marta I. Sabara Peptides corresponding to antigenic and immunogenic determinants of major neutralizing proteins of rotaviruses
GB8616174D0 (en) * 1986-07-02 1986-08-06 Antibody Technology Ltd Monoclonal antibodies
DK268889A (da) * 1988-06-07 1989-12-08 Smithkline Beckman Corp Cykliske d-cys6-peptidforbindelser, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
DE346022T1 (de) * 1988-06-10 1990-05-23 Medical Research Council, London Peptidfragmente von hiv.
FR2646425B1 (fr) * 1989-04-26 1991-08-30 Neosystem Sa Peptides synthetiques du conjugue de l'ubiquitine et de l'histone h2a
JP3058685B2 (ja) * 1989-05-08 2000-07-04 アイデックス ラボラトリーズ インコーポレーテッド ネコｔ細胞リンパトロピック レンチウィルスのポリペプチド
EP0605410B1 (en) * 1990-05-25 1995-08-16 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
CA2060699A1 (en) * 1991-02-11 1992-08-12 Isia Bursuker Gm-csf inhibiting oligopeptides

Also Published As

Publication number Publication date
GB9224684D0 (en) 1993-01-13
AU2951392A (en) 1993-06-28
DE69224750D1 (de) 1998-04-16
JPH07507045A (ja) 1995-08-03
GB9125024D0 (en) 1992-01-22
CA2123694A1 (en) 1993-06-10
FI942392L (fi) 1994-05-24
WO1993011153A1 (en) 1993-06-10
ATE163939T1 (de) 1998-03-15
EP0614464A1 (en) 1994-09-14
FI942392A7 (fi) 1994-05-24
GB2261665B (en) 1995-11-08
GB2261665A (en) 1993-05-26
AU7196596A (en) 1997-02-06
EP0614464B1 (en) 1998-03-11
FI942392A0 (fi) 1994-05-24

Similar Documents

Publication Publication Date Title
FI942005A7 (fi) Peptidianalogeja irreversiibeleinä interleukiini-1beta-proteaasi-inhibiittoreina
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
NO941629D0 (no) Peptider som inhiberer 1L-1
BR9915961A (pt) Análogos de glp-1
PT97160A (pt) Processo para a preparacao de composicoes estaveis para administracao parenterica contendo uma proteina, peptideo ou polipeptideo biologicamente activo
DK0644883T3 (da) Enniatiner og enniatinderivater til bekæmpelse af endoparasitter
DK262683A (da) Dynorphinamidanaloger
DK0792287T3 (da) Peptidanaloger af humant basisk myelinprotein
DE3853384D1 (de) Peptid.
ES2071815T3 (es) Analogos de delecion de los peptidos conocidos como magaininas.
ES2012720A6 (es) Procedimiento para la obtencion de sales de adicion de acido de taurina o glicina amidada.
ES2112921T3 (es) Peptidos y anticuerpos para el tratamiento de la artritis reumatoide.
ES2095255T3 (es) Analogos de sustitucion de peptidos magainina.
DK197989D0 (da) Peptidanaloge
ATE112289T1 (de) Hämoregulierende peptide.
ES489521A0 (es) Un procedimiento para la preparacion de un peptido
ES553691A0 (es) Procedimiento para la obtencion de un peptido.
EP0796867A4 (en) Peptide, bronchodilator and blood flow ameliorant
ATE125548T1 (de) Peptide.
ES2089182T3 (es) Solubilizacion y purificacion del receptor del peptido liberador de gastrina.
ES2058290T3 (es) Analogos de somatostatina terapeuticos.
TW336938B (en) Calcium channel blocking polypeptides from filistata hibernalis
ATE127475T1 (de) Physiologisch wirksame peptide, die eine immunoregulierende aktivität besitzen.
EP0717752A4 (en) THERAPEITIC INGREDIENTS
DK1612555T3 (da) Kryptiske peptider til anvendelse til at inducere immunologisk tolerance

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 614464

Country of ref document: ES